Windlas Biotech Ltd - Stock Valuation and Financial Performance

BSE: 543329 | NSE: WINDLAS | Pharmaceuticals & Drugs | Small Cap

Windlas Biotech Share Price

1,118.85 102.55 10.09%
as on 31-Oct'24 16:01

DeciZen - make an informed investing decision on Windlas Biotech

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Windlas Biotech stock performance -

mw4me loader
P/E Ratio (SA):
39.26
Market Cap:
2,338.4 Cr.
52-wk low:
330.7
52-wk high:
1,140

Is Windlas Biotech Ltd an attractive stock to invest in?

1. Is Windlas Biotech Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Windlas Biotech Ltd is a average quality company.

2. Is Windlas Biotech Ltd undervalued or overvalued?

The key valuation ratios of Windlas Biotech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Windlas Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Windlas Biotech Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Windlas Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Windlas Biotech Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 13.8%7.7%9.6%14.4%17.9%14.7%5.2%15%14.4%18.3%-
Value Creation
Index
0.0-0.5-0.30.00.30.1-0.60.10.00.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 259274315320288329428466513631661
Sales YoY Gr.-5.7%15.2%1.6%-10%14.1%30%9%10.1%23%-
Adj EPS 3.92.95.810.612.31315.217.52027.928.5
YoY Gr.--27%101.4%83%16.5%5.6%16.4%15.8%13.8%39.5%-
BVPS (₹) 45.186.892.6103.2106.6121109.3180.5191.1214.2219.6
Adj Net
Profit
5.64.69.216.822.523.727.638.241.857.960
Cash Flow from Ops. -2.547.36.939.122.124.911.5961109-
Debt/CF from Ops. -30.61.18.611.41.12.70.700-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.4%17%13.9%23%
Adj EPS 24.3%17.7%22.5%39.5%
BVPS18.9%15%25.1%12.1%
Share Price - - 53.1% 235.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
9.14.46.310.612.411.413.212.910.513.613.1
Op. Profit
Mgn %
9.17.57.91215.412.612.811.411.712.412.4
Net Profit
Mgn %
2.21.72.95.27.87.26.58.28.19.29
Debt to
Equity
1.20.40.40.20.20.10.2000-
Working Cap
Days
156145115118123126119140171147114
Cash Conv.
Cycle
41279103223969684170

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 13.10%

Sales growth is growing at healthy rate in last 3 years 13.85%

Net Profit is growing at healthy rate in last 3 years 22.50%

Sales growth is good in last 4 quarters at 23.31%

No data to display

Latest Financials - Windlas Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) 28.5 28.5
TTM Sales (₹ Cr.) 661 661
BVPS (₹.) 219.6 219.4
Reserves (₹ Cr.) 448 448
P/BV 5.10 5.10
PE 39.26 39.23
From the Market
52 Week Low / High (₹) 330.70 / 1139.95
All Time Low / High (₹) 203.15 / 1060.00
Market Cap (₹ Cr.) 2,338
Equity (₹ Cr.) 10.5
Face Value (₹) 5
Industry PE 46.8

Management X-Ray of Windlas Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Windlas Biotech

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales259274315320288329428466513631
Operating Expenses 235253290282244287373413453553
Manufacturing Costs791011121534365453
Material Costs195203234224181212261291299374
Employee Cost 21252933334458637087
Other Costs 12161714171719232938
Operating Profit 23202538444155536078
Operating Profit Margin (%) 9.1%7.5%7.9%12.0%15.4%12.6%12.8%11.4%11.7%12.4%
Other Income 014322371013
Interest 6755431111
Depreciation 799118913121213
Exceptional Items 000000-32000
Profit Before Tax 1161425353211465777
Tax 5158128671419
Profit After Tax 6591722245394358
PAT Margin (%) 2.2%1.7%2.9%5.3%7.8%7.2%1.2%8.3%8.3%9.2%
Adjusted EPS (₹)3.92.95.810.712.313.02.817.720.428.0
Dividend Payout Ratio (%)0%0%0%0%0%0%0%20%20%20%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 64141150167194220199393400445
Share Capital 5999666111010
Reserves 59132141158188214193382389435
Minority Interest0000000000
Debt71445130232230600
Long Term Debt17201812611000
Short Term Debt54243318172129500
Trade Payables547677755883406387131
Others Liabilities 11202525202327274049
Total Liabilities 200280303297295349296489527626

Fixed Assets

Gross Block829110111412679184164194275
Accumulated Depreciation2735455664988738596
Net Fixed Assets5556565862709691109179
CWIP 0915115008156
Investments 10951211231211272365107173
Inventories32274027194941597562
Trade Receivables68556159626479111117136
Cash Equivalents 829261318311142531
Others Assets279813132025427938
Total Assets 200280303297295349296489527626

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity -347739222511961109
PBT 1161425353211465777
Adjustment 131612151010471077
Changes in Working Capital -1929-184-9-4-40-38644
Tax Paid -7-3-2-5-13-13-7-9-10-19
Cash Flow From Investing Activity -20-62-39-11-7-14-20-154-14-92
Capex 0-13-15-11-10-15-6-15-70-38
Net Investments 00003087-14251-56
Others -20-49-23111-102352
Cash Flow From Financing Activity 26395-25-8-51130-44-15
Net Proceeds from Shares 010050016500
Net Proceeds from Borrowing 000-5-8-6-5000
Interest Paid 0-7-5-5-3-3-1-1-1-1
Dividend Paid 00000000-8-8
Others 264510-15-137-33-35-6
Net Cash Flow 324-27475-8-1532
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)9.114.516.4410.8812.5611.432.3913.0210.7513.76
ROCE (%)13.817.689.5514.3717.914.75.2215.0314.3818.31
Asset Turnover Ratio1.471.141.081.070.971.021.331.191.011.09
PAT to CFO Conversion(x)-0.59.40.782.2911.042.20.231.421.88
Working Capital Days
Receivable Days77826768777061748173
Inventory Days45403938293839394740
Payable Days97117119124134122866592107

Windlas Biotech Ltd Stock News

Windlas Biotech Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Windlas Biotech on 31-Oct-2024 16:01 is ₹1,118.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Oct-2024 16:01 the market cap of Windlas Biotech stood at ₹2,338.4.
The latest P/E ratio of Windlas Biotech as of 31-Oct-2024 16:01 is 39.26.
The latest P/B ratio of Windlas Biotech as of 31-Oct-2024 16:01 is 5.10.
The 52-week high of Windlas Biotech is ₹1,140 and the 52-week low is ₹330.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Windlas Biotech is ₹661.3 ( Cr.) .

About Windlas Biotech Ltd

Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, it provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to providing services and products in the CDMO market, it also sell its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company’s CDMO Services and Products SBV is focused on providing products and services across a diverse range of pharmaceutical and nutraceutical generic products for Indian and multinational pharmaceutical companies who market such products under their own brand names to the end users. The company’s Domestic Trade Generics and OTC Brands SBV consists of (i) trade generic products; and (ii) OTC brands, which include nutraceutical and health supplement products that do not require prescription and are marketed, distributed and promoted in India under its own brand names through online and offline channels and majorly manufactured by it. Trade generic products are generic medicines, i.e. drugs for which the patents have expired, which are sold directly to the distributor and not marketed through medical representatives, and are typically used as a substitute for more expensive branded generic medicines in order to offer affordable medicines to patients by the retailers and pharmacies. The company’s Exports SBV is engaged in identifying high growth markets and opportunities in semi-regulated international markets as well as selected regulated markets, for developing and registering product applications to obtain marketing authorizations for generic medicines and health supplements and subsequently, sell such products to pharmaceutical companies and pharmacies in the respective markets.

Business area of the company

The company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.

Awards, accreditations and recognitions

  • 2018: The company was awarded the TV100 Industrial Excellence Award in the field of medicine.
  • 2019: The company was awarded the certificate of appreciation from the Secretary, Bureau of Energy Efficiency for valuable contributions in implementing energy efficiency and cleaner production measures under the project ‘Financing Energy Efficiency at MSMEs’.
  • 2019: The company was awarded the certificate of partnership recognizing its contribution to and participation in the Swasth Bharat Yatra, a pan-India cyclothon organised by the Food Safety and Standards Authority of India.

Major events and milestones

  • 2001: Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production.
  • 2009: Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110.
  • 2010: Revenues crossed Rs 1,000 million for the FY 2009-10.
  • 2014: Received first USFDA inspection clearance for the WHC Plant.
  • 2014: Revenues crossed Rs 2,000 million for the FY 2013-14.
  • 2014: Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 110.
  • 2015: Investment of Rs 750 million from Tano India Private Equity Fund II.
  • 2017: Revenues crossed Rs 3,000 million for the FY 2016-17.
  • 2018: Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun.
  • 2018: Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun.
  • 2021: Approval of Scheme of Amalgamation of its erstwhile subsidiary, Windlas Healthcare, with and into the company.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.